In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
What percentage of patients fecal caloprotectin levels do not correlate (well or at all!) with colonoscopy results and for those patients, are there common factors that can be described.
For some patients like myself, fecal caloprotectin levels have been either borderline or normal since my surgery, but on colonoscopy active inflammation is seen (ulcers, erythema) at anastomosis or terminal ileum. It would be good to understand if there are some patients for whom this marker can't really be used to assess for recurrence of disease.
What is unique about the histology and/or immunology of fistulas that limit their response to current immunomodulator therapies?
None of the currently approved or clinical stage immunotherapies for IBD have shown to offer substantive benefits in the improvement or healing of fistulas. This is continues to be a significant gap in the non-surgical treatment of fistulizing disease.
Before the COVID crisis, I ate a restaurant meal a half-dozen times a week. During the lockdown restaurant food is rare. My Crohn's symptoms are much improved. Why? What is the relationship?
Eating in restaurants is an important part of life today. We cannot eat at home for every meal (work, school, travel, friends).
Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
Impact of Obesity on Disease Activity andPatient-Reported Outcomes Measurement InformationSystem (PROMIS) in Inflammatory Bowel Diseases